Search Videos and More

Showing 1 - 12 of 51 results

Previous| 1 | 2 | 3 ...5 |Next


ASCO 2023: Breast Cancer Research Presented by Jennifer Ligibel, MD Video

ASCO 2023: Breast Cancer Research Presented by Jennifer Ligibel, MD

Women with breast cancer shed pounds thanks to telephone-based weight loss program, clinical trial finds.
ASCO 2023: Breast Cancer Research Presented by Paolo Tarantino, MD Video

ASCO 2023: Breast Cancer Research Presented by Paolo Tarantino, MD

Data from more than 8,000 patients with stage 1A triple-negative breast cancer finds improved 5-year breast-cancer specific survival in those treated with adjuvant chemotherapy whose tumors measured between 1-2 cm.
ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD Video

ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD

Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer.
Ann Partridge, MD, MPH Presents PROs from the COMET Study Video

Ann Partridge, MD, MPH Presents PROs from the COMET Study

Patients with low-risk DCIS who underwent active monitoring had comparable physical, emotional, and psychological outcomes to patients who received standard treatment, according to results from the phase 3 COMET trial data.
Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor Video

Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor

Dana-Farber's Antonia Giordano, MD, PhD shares new data on a novel CDK4-selective inhibitor in como with letrozole as 1st line treatment in HR+/HER2 Metastatic Breast Cancer.
Breast Cancer Research at ESMO Video

Breast Cancer Research at ESMO

Dana-Farber's Sara Tolaney, MD, MPH, provides insight on DESTINY-Breast09 trial highlighted at ESMO 2021.
Jennifer Ligibel, MD Discusses Weigh Loss Intervention Video

Jennifer Ligibel, MD Discusses Weigh Loss Intervention

Dana-Farber's Jennifer Ligibel, MD reviews a telephone-based weight loss intervention that led to significant improvements in metabolic and inflammatory biomarkers associated with cancer recurrence according to new data. 
Judy Garber, MD, MPH Presents Updated Results of the OlympiA Study Video

Judy Garber, MD, MPH Presents Updated Results of the OlympiA Study

Dana-Farber’s Judy Garber, MD, MPH shared updated results from the phase 3 OlympiA study. The new analysis provides further support for olaparib’s benefits in patients with high-risk, HER2-negative breast cancer with germline mutations in BRCA1 or BRCA2.
Research Update for ER-Positive MBC | 2022-2023 EMBRACE MBC Virtual Forum Series Video

Research Update for ER-Positive MBC | 2022-2023 EMBRACE MBC Virtual Forum Series

Filipa Lynce, MD; Nikhil Wagle, MD; and Lindsay Shaw, AOCNP, ACHPN, discuss advances in research and treatment for patients with ER-positive metastatic breast cancer.
SABCS 2022: Ann Partridge, MD, MPH Video

SABCS 2022: Ann Partridge, MD, MPH

Ann Partridge, MD, MPH, led the study presented at the 2022 San Antonio Breast Cancer Symposium which showed most women participating in the study went on to deliver healthy babies.
SABCS 2022: Paolo Tarantino, MD Video

SABCS 2022: Paolo Tarantino, MD

ATEMPT study shows that 5 years after treatment, 97% of patient's w/stage 1 HER2+ breast cancer treated w/TDM1 were alive and free from invasive disease and 98.3% had no recurrence of their cancer.
SABCS 2022: Rachel Freedman, MD, MPH Video

SABCS 2022: Rachel Freedman, MD, MPH

Rachel Freedman, MD, MPH, shared results from the TBCRC 022 study where Neratinib in combination w/T-DM1 showed promising activity in patients w/heavily pre-treated HER2+ breast cancer metastatic to the central nervous system.

Showing 1 - 12 of 51 results

Previous| 1 | 2 | 3 ...5 |Next